Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 696 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis, Chronic Clear all

Conditions: Hepatitis C, Chronic
Interventions: RO5024048, RO5190591, RO5466731, ribavirin [Copegus], ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 15
States / cities: La Jolla, California • Englewood, Colorado • South Miami, Florida + 11 more

Conditions: Hepatitis C Virus
Interventions: Asunaprevir, Daclatasvir, Peg-interferon Alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 20
States / cities: Montgomery, Alabama • La Jolla, California • Los Angeles, California + 16 more

Conditions: Genotype 1 Chronic Hepatitis C
Interventions: GI-5005, Pegylated Interferon and Ribavirin; Drug
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 25
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 21 more

Conditions: Hepatitis C Virus Infection
Interventions: Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 10
States / cities: Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more

Conditions: Hepatitis B
Interventions: Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts GS-9620; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 9
States / cities: Phoenix, Arizona • Indianapolis, Indiana • New Orleans, Louisiana + 6 more

Conditions: Chronic Hepatitis C
Interventions: SOF, RBV, Placebo to match SOF, Placebo to match RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 50
States / cities: Birmingham, Alabama • Coronado, California • Los Angeles, California + 40 more

Conditions: Hepatitis B Virus (HBV)
Interventions: Tenofovir disoproxil fumarate (TDF), Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 3
States / cities: Oakland, California • Indianapolis, Indiana • Seattle, Washington

Conditions: Chronic Hepatitis C, Organ Transplantation, Immunosuppression
Interventions: Neoral, Tacrolimus; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hepatitis B
Interventions: Bepirovirsen, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Bakersfield, California • San Francisco, California • Orlando, Florida + 4 more

Conditions: Chronic Hepatitis, Delta Virus
Interventions: Brelovitug; Biological
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hepatitis C, Chronic, Hepatitis C, Thrombocytopenia
Interventions: SB497115, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 9
States / cities: Denver, Colorado • Boston, Massachusetts • Detroit, Michigan + 6 more

Conditions: Chronic Hepatitis Delta
Interventions: Bulevirtide; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: New York, New York

Conditions: Chronic Hepatitis C
Interventions: SOF/LDV (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), EBR/GZR (elbasvir/grazoprevir), Ribavirin; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 1,275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 38
States / cities: Little Rock, Arkansas • Palo Alto, California • San Diego, California + 27 more

Conditions: All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 17,667 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Hepatitis C Infection
Interventions: Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin, Ombitasvir mini tablet, Paritaprevir mini tablet, Ritonavir mini tablet, Dasabuvir mini tablet, Ribavirin solution; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 7 more

Conditions: Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions: Cannabis, Medical, RYAH-Medtech Inhaler; Drug · Device
Lead sponsor: OMNI Medical Services, LLC; Network
Eligibility: 7 Years and older
Enrollment: 200,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 17
States / cities: Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more

Conditions: Hepatitis C
Interventions: Alisporivir, Peginterferon alfa-2a, Ribavirin, ALV Placebo; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,081 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 32
States / cities: Beverly Hills, California • Oakland, California • San Diego, California + 23 more

Conditions: Hepatitis C
Interventions: telaprevir, ribavirin, peginterferon alfa-2a; Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 57 more

Conditions: Hepatitis C
Interventions: MBT and BreathID; Other
Lead sponsor: Meridian Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: New York, New York • Houston, Texas • Richmond, Virginia

Conditions: HCV HIV
Interventions: Ledipasvir 90 mg and Sofosbuvir 400 mg; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Hepatitis C
Interventions: GI-5005; Biological
Lead sponsor: GlobeImmune; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 5
States / cities: Pasadena, California • Denver, Colorado • Miami, Florida + 2 more

Conditions: Hepatitis C, Chronic
Interventions: Viramidine, Peginterferon alfa-2b; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 11
States / cities: Los Angeles, California • San Mateo, California • Bradenton, Florida + 8 more

Conditions: Hepatitis C
Interventions: TMC435, PSI-7977 (GS7977), Ribavirin; Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 22
States / cities: Hoover, Alabama • Bakersfield, California • La Jolla, California + 19 more

Conditions: Chronic Hepatitis b
Interventions: ATI-2173 50 mg; Drug
Lead sponsor: Antios Therapeutics, Inc; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Cypress, California

Search by objective public record fields.

ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment

Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection

Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon

Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection

Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

Expanded-Access Program for the Treatment of Chronic Hepatitis D With Brelovitug

SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C

Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)

Study of Oral Treatments for Hepatitis C

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

Outcomes Mandate National Integration With Cannabis as Medicine

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

BreathID Multi-center HCV Liver Breath Test Study

Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection

Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C

A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients

Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects